KRTX Karuna Therapeutics Inc

Price (delayed)

$133.17

Market cap

$3.98B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$5.78

Enterprise value

$3.81B

Karuna Therapeutics is a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions.Karuna understand there is a need for differentiated and ...

Highlights
The debt has surged by 181% year-on-year but it has declined by 7% since the previous quarter
The company's quick ratio has shrunk by 68% YoY but it rose by 13% QoQ
The net income has plunged by 90% YoY and by 19% from the previous quarter
KRTX's EPS has dropped by 72% year-on-year and by 17% since the previous quarter

Key stats

What are the main financial stats of KRTX
Market
Shares outstanding
29.88M
Market cap
$3.98B
Enterprise value
$3.81B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
8.74
Price to sales (P/S)
107.38
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
103.07
Earnings
Revenue
$36.96M
EBIT
-$171.52M
EBITDA
-$170.88M
Free cash flow
-$132.53M
Per share
EPS
-$5.78
Free cash flow per share
-$4.45
Book value per share
$15.24
Revenue per share
$1.24
TBVPS
$15.92
Balance sheet
Total assets
$474.47M
Total liabilities
$20.79M
Debt
$6.98M
Equity
$453.69M
Working capital
$448.72M
Liquidity
Debt to equity
0.02
Current ratio
29.18
Quick ratio
27.85
Net debt/EBITDA
0.99
Margins
EBITDA margin
-462.3%
Gross margin
100%
Net margin
-464%
Operating margin
-466.6%
Efficiency
Return on assets
-32.4%
Return on equity
-33.7%
Return on invested capital
-62%
Return on capital employed
-37.4%
Return on sales
-464%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

KRTX stock price

How has the Karuna Therapeutics stock price performed over time
Intraday
1.77%
1 week
5.26%
1 month
21.06%
1 year
12.05%
YTD
1.66%
QTD
5.26%

Financial performance

How have Karuna Therapeutics's revenue and profit performed over time
Revenue
$36.96M
Gross profit
$36.96M
Operating income
-$172.48M
Net income
-$171.53M
Gross margin
100%
Net margin
-464%
The net income has plunged by 90% YoY and by 19% from the previous quarter
The operating income has dropped by 88% year-on-year and by 20% since the previous quarter
KRTX's operating margin is down by 20% from the previous quarter
The net margin has declined by 19% since the previous quarter

Growth

What is Karuna Therapeutics's growth rate over time

Valuation

What is Karuna Therapeutics stock price valuation
P/E
N/A
P/B
8.74
P/S
107.38
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
103.07
KRTX's EPS has dropped by 72% year-on-year and by 17% since the previous quarter
The equity has declined by 22% year-on-year and by 10% since the previous quarter
The price to book (P/B) is 18% more than the last 4 quarters average of 7.3

Efficiency

How efficient is Karuna Therapeutics business performance
Karuna Therapeutics's ROIC has plunged by 86% YoY and by 13% from the previous quarter
Karuna Therapeutics's return on equity has shrunk by 54% YoY and by 27% QoQ
The return on assets has dropped by 51% year-on-year and by 26% since the previous quarter
KRTX's return on sales is down by 19% since the previous quarter

Dividends

What is KRTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for KRTX.

Financial health

How did Karuna Therapeutics financials performed over time
KRTX's total liabilities has soared by 149% YoY but it is down by 19% from the previous quarter
The company's quick ratio has shrunk by 68% YoY but it rose by 13% QoQ
The debt is 98% smaller than the equity
The debt has surged by 181% year-on-year but it has declined by 7% since the previous quarter
The debt to equity has surged by 100% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.